SCHEMBL3560764

SCHEMBL3560764

O=C(Nc1ccc(Cl)cc1)NC(C(=O)NC1=CCC(=NN2CCCC2)C=C1)c1ccccc1Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.36
CNR1 P21554 9/20 0.35
MAPT P10636 5/20 0.35
KDM4E B2RXH2 3/20 0.35
NPSR1 Q6W5P4 3/20 0.35
MEN1 O00255 2/20 0.35
GAA P10253 2/20 0.35
KMT2A Q03164 2/20 0.35
LMNA P02545 1/20 0.35
XBP1 P17861 1/20 0.35
HTT P42858 1/20 0.35
PAX8 Q06710 1/20 0.35
CNR2 P34972 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
FPR1 P21462 1/20 0.33
FPR2 P25090 1/20 0.33
LIPG Q9Y5X9 1/20 0.33
NPC1 O15118 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3566171 0.91 CNR1 (0.34) SMN1; SMN2CNR1NPSR1CNR2ALDH1A1
SCHEMBL3566653 0.91 CNR1 (0.36) CNR1MAPTKDM4ENPSR1MEN1
SCHEMBL3567223 0.91 CNR1 (0.34) SMN1; SMN2CNR1MAPTMEN1KMT2A
SCHEMBL3561031 0.91 CNR2 (0.35) CNR1MAPTKDM4ENPSR1MEN1
SCHEMBL3560271 0.91 CYP1A2 (0.35) SMN1; SMN2CNR1MAPTKDM4ENPSR1
SCHEMBL3570075 0.91 MAPT (0.38) SMN1; SMN2CNR1MAPTNPSR1MEN1
SCHEMBL3556133 0.90 FPR2 (0.40) SMN1; SMN2CNR1MAPTKDM4ENPSR1
SCHEMBL3563086 0.88 FPR2 (0.40) SMN1; SMN2CNR1MAPTHTTALDH1A1
SCHEMBL3562894 0.85 SMN1; SMN2 (0.40) SMN1; SMN2CNR1MAPTMEN1KMT2A
SCHEMBL3564956 0.84 SMN1; SMN2 (0.40) SMN1; SMN2CNR1MAPTKDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 SMN1; SMN2 4448/4885CNR1 1500/4885MAPT 1933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.